Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition

Abstract

Antifolates, folate analogs that inhibit vitamin B 9 (folic acid)-using cellular enzymes, have been used over several decades for the treatment of cancer and inflammatory diseases. Cellular uptake of the antifolates in clinical use occurs primarily via widely expressed facilitative membrane transporters. More recently, human folate receptors (FRs), high affinity receptors that transport folate via endocytosis, have been proposed as targets for the specific delivery of new classes of antifolates or folate conjugates to tumors or sites of inflammation. The development of specific, FR-targeted antifolates would be accelerated if additional biophysical data, particularly structural models of the receptors, were available. Here we describe six distinct crystallographic models that provide insight into biological trafficking of FRs and distinct binding modes of folate and antifolates to these receptors. From comparison of the structures, we delineate discrete structural conformations representative of key stages in the endocytic trafficking of FRs and propose models for pH-dependent conformational changes. Additionally, we describe the molecular details of human FR in complex with three clinically prevalent antifolates, pemetrexed (also Alimta), aminopterin, and methotrexate. On the whole, our data form the basis for rapid design and implementation of unique, FR-targeted, folate-based drugs for the treatment of cancer and inflammatory diseases.isothermal titration calorimetry | targeted drug delivery

Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus

“…So far, only the FR-α and FR-β isoforms have been conclusively shown to display receptor binding functionality, that is, the ability to bind/internalize physiological folates with high specificity (8). While FR-α is frequently overexpressed by cancer cells of epithelial origins (7,8), FR-β is mostly expressed in functional form by activated macrophages (and their monocyte precursors) during inflammatory episodes that can lead to irreversible tissue and joint damage (9,10). Thus, FR-β-expressing macrophages have emerged as a promising target for antibody-or ligand-mediated drug delivery to control local and systemic inflammation (11).…”

Controlled release of targeted anti-leukemia drugs azacitidine and decitabine monitored using surface-enhanced Raman scattering (SERS) spectroscopy

“…In the case of AML, several receptors overexpressed in cancer cells have been considered for cancer cell recognition, including a family of folate receptors (FR) 26,27 , with most common FR and FR, which share most of the homology and are anchored in the cell membrane through glycosyl phosphatidinylinositol linkages. They show similar folate binding ability, as well as the same mechanism of endocytosis-based folate internalization 28 . The convenient binding chemistry and lack of immunogenicity make the folate ligands one of the best choices for targeting cancer cells 19,[29][30][31] .…”

Antimetabolites That Interfere with Nucleic Acid Biosynthesis

“…The high-affinity human folate receptors (FRs), which transport folate via endocytosis, have been proposed as targets for the specific delivery of antifolates or folate conjugates to tumors. 54 Some cyclopenta[g]quinazoline derivatives with activity as inhibitors of thymidylate synthase have been proven to have good α-FR/RFC selectivity and therefore are good candidates for the development of antifolates specifically targeted at α-FR-overexpressing tumors. One of these compounds is CB-300638, which was designed on the basis of the crystal structures of inhibitors bound to TS 55 and has shown promising preclinical data, including experimental proof of its selective delivery into human tumor cell lines overexpressing the α-isoform of the folate receptor.…”